OncoTargets and Therapy · 2016 · 49 citations · 37 references
MedicineOncologyBreast OncologyCancer EpidemiologyHematologic OncologyCancer BiomarkersCancer Survival AnalysisImmuno-oncology BiomarkersBreast Cancer PrognosisDisease-free Survival AnalysisDisease-free Survival AssessmentHormone Receptor - Positive Breast CancerKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesNeutrophil-to-lymphocyte RatioPlatelet-to-lymphocyte Ratio
PURPOSE: We aimed to investigate the relationship between pretreatment neutrophil-to-lymphocyte ratio (NLR)/platelet-to-lymphocyte ratio (PLR) and the estimation of hormone-receptor-negative (HR-) breast cancer patients' survival in a Chinese cohort. PATIENTS AND METHODS: Of 434 consecutive HR- nonmetastatic breast cancer patients treated between 2004 and 2010 in the Affiliated Hospital of Academy of Military Medical Sciences, 318 eligible cases with complete data were included in the present study. Kaplan-Meier analysis was performed to determine the overall survival (OS) and disease-free survival (DFS). Univariate and multivariate Cox proportional hazards models were used to test the usefulness of NLR and PLR. RESULTS: Univariate analysis indicated that both elevated NLR and PLR (both P<0.001) were associated with poor OS. The utility of NLR remained in the multivariate analysis (P<0.001), but not PLR (P=0.104). The analysis results for DFS were almost the same as OS. Subgroup analysis revealed a significant association between increased NLR and PLR (P<0.001 and P=0.011) and poor survival in triple-negative breast cancer. However, for human epidermal growth factor receptor 2-positive breast cancer, only NLR was significantly associated with OS in the multivariate analysis (P=0.001). CONCLUSION: The present study indicates that both increased NLR and PLR are associated with poor survival in HR-breast cancer patients. Meanwhile, NLR is independently correlated with OS and DFS, but PLR is not.
37
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Hallmarks of Cancer: The Next Generation
Michael F. Roizen · Yearbook of Anesthesiology and Pain Management · 2012 · 1.5K citations
Medicine, Cancer Biology, Oncology +12
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert J. Gray, Della Makower et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text
Medicine, Oncology, Breast Oncology +16
Sylvia Adams, Robert J. Gray, Sandra Demaria et al. · Journal of Clinical Oncology · 2014 · 1.3K citations · Full text
Medicine, Immunology, Oncology +17